OnKure Therapeutics, Inc. (OKUR) Stock Analysis & Investment Frameworks
OnKure Therapeutics, Inc. (OKUR) stock analysis on Invetso. Review OnKure Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
OnKure Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
OnKure Therapeutics, Inc. Key Financial Metrics
- Market Cap: $93.14M
- Revenue: $N/A
- ROE: -49.02%
- ROIC: -35.91%
- Dividend Yield: N/A
About OnKure Therapeutics, Inc.
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
OnKure Therapeutics, Inc. Investment Frameworks
Invetso analyzes OnKure Therapeutics, Inc. (OKUR) across the following frameworks:
- OnKure Therapeutics, Inc. 10Y Growth Potential
- OnKure Therapeutics, Inc. Scenario Analysis
- OnKure Therapeutics, Inc. Risks & Opportunities
- OnKure Therapeutics, Inc. Economic Moat
- OnKure Therapeutics, Inc. Business Model
- OnKure Therapeutics, Inc. Management
- OnKure Therapeutics, Inc. SWOT Analysis
- OnKure Therapeutics, Inc. Porter's 5 Forces
- OnKure Therapeutics, Inc. PESTLE Analysis
- OnKure Therapeutics, Inc. ESG Analysis